This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
This guidance document includes an updated summary of diagnostic PCR and serology together with detailed information on isolation, culture, identification and epidemiological typing of B. pertussis to help users choose the best methods within the local technical and financial provisions.
Version 6.1 is the final protocol for the third EU-wide point prevalence survey in acute care hospitals (PPS 2022–2023). It contains important changes compared to protocol version 5.3 (PPS 2016–2017), including on healthcare-associated COVID-19.
This key provides the non-specialist with reference material to help recognise an invasive mosquito species and gives details on the morphology to help with verification.
This reporting protocol is intended for reporting national case-based data for surveillance of hepatitis of unknown origin from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA), to the European level.
This document provides guidance on diagnostic testing, molecular characterisation and metagenomic analysis for suspect cases of severe acute hepatitis of unknown aetiology.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.